title: Studies on the response of growth hormone (GH) secretion to GH-releasing hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone, and somatostatin in acromegaly.
abstract: The plasma GH response to GH-releasing hormone (GHRH), TRH, or GnRH administration was examined in 25 acromegalic patients. Plasma GH levels increased in 21 patients after GHRH, in 19 after TRH, and in 4 after GnRH. The four GHRH nonresponders had had acromegaly longer than had the GHRH responders. No specific combination of GH responsiveness to these 3 releasing hormones was found among the patients. Infusion of 1 mg GHRH for 150 min gradually increased plasma GH levels, with some fluctuations, from the beginning to the end of infusion in normal subjects and in 7 patients who were GHRH responders, but a bolus injection of 100 micrograms GHRH at the end of the infusion did not further elevate plasma GH levels. These results suggest that desensitization to GHRH occurred in the normal subjects and acromegalic patients. However, in 5 acromegalic patients who responded to both GHRH and TRH, a bolus injection of 500 micrograms TRH given at the end of the 150-min infusion of 1 mg GHRH evoked a further plasma GH rise. In 5 normal subjects and 2 patients who were responders to GHRH but not TRH, a bolus injection of 500 micrograms TRH did not cause plasma GH elevation at the end of 150-min infusion of 1 mg GHRH. These results imply that TRH and GnRH stimulate GH secretion from the adenoma cells in vivo through receptors different from those for GHRH. In vitro studies using cultured pituitary adenoma cells from 2 patients revealed that the responses of GH secretion to GHRH were similar to those in vivo. These data, therefore, suggest that the responsiveness of GH secretion to stimuli is determined by the specificity of the receptors on adenoma cells. The action of somatostatin-28 was more potent than that of somatostatin-14 in the suppression of GH secretion from adenoma cells.
authors.forename: T
authors.initials: T
authors.lastname: Shibasaki
authors.forename: M
authors.initials: M
authors.lastname: Hotta
authors.forename: A
authors.initials: A
authors.lastname: Masuda
authors.forename: T
authors.initials: T
authors.lastname: Imaki
authors.forename: N
authors.initials: N
authors.lastname: Obara
authors.forename: N
authors.initials: N
authors.lastname: Hizuka
authors.forename: K
authors.initials: K
authors.lastname: Takano
authors.forename: I
authors.initials: I
authors.lastname: Wakabayashi
authors.forename: H
authors.initials: H
authors.lastname: Demura
authors.forename: N
authors.initials: N
authors.lastname: Ling
mesh_terms: D000172:Acromegaly / Q000209:etiology / Q000378:metabolism*; D000236:Adenoma / Q000150:complications / Q000378:metabolism; D000328:Adult; D000368:Aged; D007987:Gonadotropin-Releasing Hormone; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism*; D013007:Growth Hormone-Releasing Hormone; D006801:Humans; D066298:In Vitro Techniques; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000150:complications / Q000378:metabolism; D011863:Radioimmunoassay; D013004:Somatostatin / Q000494:pharmacology; D053561:Somatostatin-28; D013973:Thyrotropin-Releasing Hormone
chemical_list: D007987:Gonadotropin-Releasing Hormone; D013004:Somatostatin; D013973:Thyrotropin-Releasing Hormone; D053561:Somatostatin-28; D013006:Growth Hormone; D013007:Growth Hormone-Releasing Hormone